If you want to test a drug, the liver processes 99% of all drugs 1st Pass in glucuronidation and the kidney's the remaining 1%. Hence ONVO is hitting the sweet spot with simulating liver (and soon kidney cells). Value in ONVO is in rapid drug screening. This is where ONVO will make ALL it's money is screening small molecules for toxicity for the next 5-10 years. ONVO will start transplanting tissue in disease ridden organs within a decade but that is after some major collaborations not yet on the market. Another area for ONVO : Autodesk & ONVO are working together to use their 3D software to help create structure for the growth of blood vessels which is the first step in creating viable tissue that lasts more than 96 hours.